Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, December 4, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, December 1, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Debjit Chattopadhyay Initiated (SRPT) at Strong Buy and Held Target at $75 on, Dec 1st, 2017
Published on 2024-10-26 01:17:26 - WOPRAI, Debjit Chattopadhyay
Debjit Chattopadhyay of HC Wainwright & Co., Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $75 on, Dec 1st, 2017.
Debjit has made no other calls on SRPT in the last 4 months.
There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Debjit's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Maintained at Hold with Increased Target to $49 on, Thursday, October 26th, 2017
These are the ratings of the 2 analyists that currently disagree with Debjit
- Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Monday, October 2nd, 2017
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017
